Novo Nordisk has experienced a notable increase of over 45% in its stock value over the past month. This surge is linked to optimistic sales forecasts and the approval of its Wegovy product for larger doses in the UK. Such rapid movements shift the focus to how the stock interacts with specific technical resistance levels.
Two main resistance levels are observed. The first is around $69, connected to a gap fill from July 29 of the previous year. This level may indicate where stock price could pause or consolidate. The second level is near $74, linked to another gap fill from June 20 last year, serving as another potential area where resistance could occur.
Novo Nordisk, a pharmaceutical company, has gained attention due to the success of Wegovy, which has influenced recent stock performance. The stock pays a quarterly dividend projected to reach $1.73 per share by 2026, a significant increase of over 19% from the August dividend. Despite the momentum, maintaining disciplined risk management remains essential in decision-making, with emphasis on technical factors rather than external news.
We recall the strong 45% momentum run in Novo Nordisk during 2025, which was driven by early optimism around its product pipeline. Today, with the stock trading near $92.50, the technical picture has changed, and our focus shifts to managing positions at these new highs. The key resistance levels near $69 and $74 from last year were overcome, and they now serve as potential support zones on any significant pullback.
This current strength is backed by solid fundamentals, as Novo Nordisk just reported a 38% year-over-year revenue increase for the fourth quarter of 2025. This growth was driven by its GLP-1 drugs, as supply constraints that we saw through parts of last year have largely been resolved. This allows us to have more confidence in the sustainability of the current trend.
For derivative traders, the elevated price makes selling premium an attractive strategy. We are looking at selling cash-secured puts with strike prices near the $85 support level to either collect income or get into the stock at a better price. This approach takes advantage of the implied volatility that remains firm following the recent earnings announcement.
Alternatively, for those already holding the stock, writing covered calls with a strike price near the psychological $100 level for February expiration could be a sound move. This allows for participation in further upside while generating yield from the position. Given the stock’s run, this strategy also provides a small hedge against a minor downturn.
We must also factor in the competitive environment, as recent industry data shows Eli Lilly’s Zepbound has captured nearly 40% of the new-to-brand prescription market for anti-obesity drugs. This intense competition could lead to volatility spikes, making strategies like long-dated straddles interesting for those who expect a big move but are unsure of the direction. This market share battle will be a key factor to watch throughout the first half of 2026.
Finally, the company’s strong cash flow underpins the upcoming dividend, which is on track to increase to the projected $1.73 per share this year. This provides a fundamental cushion that can limit downside risk, making it slightly safer to sell options premium. We see this dividend as a key support for investor sentiment in the coming months.
